Halozyme Therapeutics | HALO - Gross Profit On Sales

Halozyme Therapeutics reported $139.38M in Gross Profit on Sales for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US USD 134.08M 5.5M
Agios Pharmaceuticals AGIO:US USD 3.9M 898K
Alnylam Pharmaceuticals ALNY:US USD 283.77M 60.58M
Amarin AMRN:US USD 65.94M 7.31M
Amgen AMGN:US USD 5.09B 28M
Baxter International BAX:US USD 1.47B 322M
Cara Therapeutics CARA:US USD 1.13M 6.63M
Eli Lilly And LLY:US USD 5.75B 391.2M
Esperion Therapeutics ESPR:US USD 14.66M 2.18M
Halozyme Therapeutics HALO:US USD 139.38M 22.28M
Intercept Pharmaceuticals ICPT:US USD 77.19M 27K
Intra Cellular Therapies ITCI:US USD 81.08M 15.06M
Intrexon XON:US USD 506K 14.64M
IONIS PHARMACEUT IONS:US USD 148.2M 10.05M
JAZZ PHA JAZZ:US USD 804.76M 2.23M
Mannkind MNKD:US USD 19.93M 4.57M
Nektar Therapeutics NKTR:US USD 15.79M 2.86M
Peregrine Pharmaceuticals PPHM:US USD 9.82M 5.68M
Pfizer PFE:US USD 14.47B 2.08B
United Therapeutics UTHR:US USD 432.7M 46.1M
Vanda Pharmaceuticals VNDA:US USD 58.24M 754K